Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization
| Status: | Withdrawn |
|---|---|
| Conditions: | Infectious Disease, Hospital |
| Therapuetic Areas: | Immunology / Infectious Diseases, Other |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/13/2018 |
| Start Date: | May 2009 |
| End Date: | October 2009 |
Prevalence of Methicillin-resistant Staphylococcus Aureus (MRSA) in a Medical Center and Efficacy of Altabax in Clearing MRSA Nasal Colonization
The purpose of the study is to determine whether Altabax (retapamulin ointment, 1%) is
effective in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) nasal
colonization. The hypothesis is that the prevalence of MRSA increases as a function of
increasing clinical exposure and that the topical antibiotic Altabax is efficacious in
clearing MRSA nasal colonization. The prevalence of MRSA nasal colonization among Tulane
University medical students and residents and physicians of Tulane Medical Center and Ochsner
Medical Center will be investigated. A total of 300 subjects will be recruited for the study.
After giving informed consent, subjects will be swabbed to obtain specimens for culture and
asked to complete a short survey to assess risk factors. Swabs will be used to directly
inoculate three types of plates: CHROMagar MRSA plates, Spectra MRSA plates, and TSA with
sheep blood plates. After appropriate incubation, Staph latex slide tests will be done and
then results confirmed with cefoxitin disk susceptibility testing. MRSA positive subjects
will be offered a treatment protocol with the topical antibiotic Altabax (retapamulin
ointment, 1%) to be applied as a thin layer to the anterior nares twice daily for 5 days.
After the 5-day treatment is complete, subjects will be retested for the presence of MRSA at
day 7, day 12, day 30, and day 90. For this portion of the study, all cultures will
additionally undergo disk susceptibility testing for retapamulin, erythromycin, clindamycin
(including D-test), trimethoprim sulfa, and mupirocin (5 mcg and 20 mcg disks). In addition,
Etests for retapamulin and mupirocin will be done. Genetic isolates will be characterized by
rep-PCR pre-treatment and post-treatment. Data will be analyzed for MRSA prevalence and risk
factor associations with MRSA colonization. Of those subjects found to be MRSA positive, data
from the follow-up cultures will be used to assess the efficacy of Altabax in clearing MRSA
nasal colonization.
effective in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) nasal
colonization. The hypothesis is that the prevalence of MRSA increases as a function of
increasing clinical exposure and that the topical antibiotic Altabax is efficacious in
clearing MRSA nasal colonization. The prevalence of MRSA nasal colonization among Tulane
University medical students and residents and physicians of Tulane Medical Center and Ochsner
Medical Center will be investigated. A total of 300 subjects will be recruited for the study.
After giving informed consent, subjects will be swabbed to obtain specimens for culture and
asked to complete a short survey to assess risk factors. Swabs will be used to directly
inoculate three types of plates: CHROMagar MRSA plates, Spectra MRSA plates, and TSA with
sheep blood plates. After appropriate incubation, Staph latex slide tests will be done and
then results confirmed with cefoxitin disk susceptibility testing. MRSA positive subjects
will be offered a treatment protocol with the topical antibiotic Altabax (retapamulin
ointment, 1%) to be applied as a thin layer to the anterior nares twice daily for 5 days.
After the 5-day treatment is complete, subjects will be retested for the presence of MRSA at
day 7, day 12, day 30, and day 90. For this portion of the study, all cultures will
additionally undergo disk susceptibility testing for retapamulin, erythromycin, clindamycin
(including D-test), trimethoprim sulfa, and mupirocin (5 mcg and 20 mcg disks). In addition,
Etests for retapamulin and mupirocin will be done. Genetic isolates will be characterized by
rep-PCR pre-treatment and post-treatment. Data will be analyzed for MRSA prevalence and risk
factor associations with MRSA colonization. Of those subjects found to be MRSA positive, data
from the follow-up cultures will be used to assess the efficacy of Altabax in clearing MRSA
nasal colonization.
Inclusion Criteria:
- Subjects must be either a student, resident, or physician at Tulane University or be a
resident or physician at Ochsner Medical Center.
Exclusion Criteria:
- Subjects who are pregnant or who are presently taking antibiotics or require treatment
with systemic antibiotics at anytime during the course of the study.
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials